Next Article in Journal
Host-Defense Peptides with Therapeutic Potential from Skin Secretions of Frogs from the Family Pipidae
Previous Article in Journal
Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction?
Previous Article in Special Issue
Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease
Pharmaceuticals 2014, 7(1), 46-57; doi:10.3390/ph7010046
Article

Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways

1,2,* , 1,2
, 3
, 4
, 5
, 1,2
, 1,2
, 6
, 7
, 1
 and 1,2
Received: 15 November 2013; in revised form: 20 December 2013 / Accepted: 2 January 2014 / Published: 9 January 2014
(This article belongs to the Special Issue Drug Repositioning)
View Full-Text   |   Download PDF [845 KB, uploaded 9 January 2014]   |   Browse Figures
Abstract: Recent observations suggest a lower incidence of malignancies in patients infected with HIV during treatment with Highly Active Anti-Retroviral Therapy (HAART) utilizing protease inhibitors. We investigated the effects of ritonavir, a FDA approved HIV protease inhibitor, on proliferation of pancreatic ductal adeno-carcinoma (PDAC) cell lines. Human PDAC cell lines BxPC-3, MIA PaCa-2, and PANC-1 were propagated under standard conditions and treated with serial dilutions of ritonavir. Ritonavir inhibited cell growth in a dose-dependent manner as well as activated the intrinsic apoptotic pathway in human pancreatic ductal adenocarcinoma (PDAC) cell lines. We observed down-modulation of cell-cycle promoting and up-regulation of cell-cycle inhibitory genes; enhanced interaction of retinoblastoma protein (RB) with E2F-1 transcription factor; inhibition of phosphorylation of RB, resulting in sequestration of E2F-1 and subsequent down-regulation of S phase genes; decreased interaction of E2F-1 with its consensus binding sites; inhibition of cell motility and invasiveness; and inhibition of the AKT pathway. Our results demonstrate a potential use of ritonavir as part of combination chemotherapy for PDAC. Since ritonavir is FDA approved for HIV, drug repositioning for PDAC would limit the costs and reduce risks.
Keywords: ritonavir; pancreatic adenocarcinoma; AKT; retinoblastoma; 2F-1 ritonavir; pancreatic adenocarcinoma; AKT; retinoblastoma; 2F-1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Batchu, R.B.; Gruzdyn, O.V.; Bryant, C.S.; Qazi, A.M.; Kumar, S.; Chamala, S.; Kung, S.T.; Sanka, R.S.; Puttagunta, U.S.; Weaver, D.W.; Gruber, S.A. Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways. Pharmaceuticals 2014, 7, 46-57.

AMA Style

Batchu RB, Gruzdyn OV, Bryant CS, Qazi AM, Kumar S, Chamala S, Kung ST, Sanka RS, Puttagunta US, Weaver DW, Gruber SA. Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways. Pharmaceuticals. 2014; 7(1):46-57.

Chicago/Turabian Style

Batchu, Ramesh B.; Gruzdyn, Oksana V.; Bryant, Christopher S.; Qazi, Aamer M.; Kumar, Sanjeev; Chamala, Sreedhar; Kung, Shu T.; Sanka, Ramana S.; Puttagunta, Udaya S.; Weaver, Donald W.; Gruber, Scott A. 2014. "Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways." Pharmaceuticals 7, no. 1: 46-57.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert